Loading...
Loading...
ALIM| Name | Value |
|---|---|
| Revenues | 13.6M |
| Cost of Revenue | 2.0M |
| Gross Profit | 11.6M |
| Operating Expense | 15.0M |
| Operating I/L | -3.4M |
| Other Income/Expense | -1.8M |
| Interest Income | 0.0M |
| Pretax | -5.2M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -5.3M |
Alimera Sciences, Inc. is a pharmaceutical company specializing in ophthalmic pharmaceuticals. Its flagship product, ILUVIEN, is an intravitreal implant used to treat diabetic macular edema and prevent relapse in recurrent non-infectious uveitis. The company generates revenue by selling its products directly to physician offices, pharmacies, and hospitals through a combination of direct sales and distributors. Additionally, Alimera Sciences has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop and sell insert technology for delivering corticosteroids to the back of the eye for various eye diseases and diabetic macular edema treatment.
